Australia's Orthocell rises as flagship product records first Thailand sales

Orthocell

21/09/2026 02:22

** Shares of Orthocell OCC.AX rise as much as nearly 8% to A$0.745, marking their highest level since September 1
** Shares on track for their best day since August 11, if gains hold
** The regenerative medicine achieves first commercial sales of flagship product Remplir in Thailand
** About 442,385 shares change hands, 1.9x the 30-day average of 238,579
** Stock down 33.4%, YTD, including moves in current session

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)
 ((Jasmeenaraislam.Shaikh@thomsonreuters.com;))